Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 5/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4714383 | 0.83 | PRKAB2 (0.44) | PARP1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL7111930 | 0.83 | DRD2 (0.46) | ALDH1A1KDM4EHPGDHSD17B10DRD2 | |
| SCHEMBL4224918 | 0.81 | HTR7 (0.43) | ALDH1A1KDM4EHPGDHSD17B10HTR7 | |
| SCHEMBL8492014 | 0.80 | PARP1 (0.43) | PARP1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL13925631 | 0.79 | MAOA (0.64) | ALDH1A1KDM4EHPGDHSD17B10MAOA | |
| SCHEMBL13925633 | 0.79 | MAOA (0.64) | ALDH1A1KDM4EHPGDHSD17B10MAOA | |
| SCHEMBL13925630 | 0.79 | MAOA (0.64) | ALDH1A1KDM4EHPGDHSD17B10MAOA | |
| SCHEMBL4596031 | 0.78 | PARP1 (0.54) | PARP1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL4226542 | 0.77 | PRKAB2 (0.63) | ALDH1A1KDM4EHPGDHTR7DRD2 | |
| SCHEMBL4596960 | 0.77 | HPGD (0.56) | ALDH1A1KDM4EHPGDHSD17B10HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623407-B2 | Gabapentin-containing solid compositions and process for preparing the same | PFIZER INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623407-B2 | Gabapentin-containing solid compositions and process for preparing the same | PFIZER INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20090156677-A1 | Gabapentin-containing Solid Compositions and Process for Preparing the Same | PFIZER INC | 2009-06-18 | — | — | US | disclosed |
| US-20090156677-A1 | Gabapentin-containing Solid Compositions and Process for Preparing the Same | PFIZER INC | 2009-06-18 | — | — | US | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156677-A1 | Gabapentin-containing Solid Compositions and Process for Preparing the Same | GABRD, GABRA6, GABRB1 | PARP1 4644/4885ALDH1A1 485/4885KDM4E 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.